Sunday, August 16, 2026
RSS

Pharmaceutical

Iovance Biotherapeutics' Q2 Earnings: Strong Momentum in Oncology

Iovance Biotherapeutics showcases promising developments in oncology, highlighted by a key FDA designation and strong clinical response rates.

By Marcus Rivera • August 16, 2026
Tech

Intel and Nvidia Lead AI Surge: Insights for Tech Investors

Intel and Nvidia drive market activity as inflation moderates, boosting tech sectors. Key insights for investors in US and Canadian markets.

Sarah Chen • Aug 16
Pharmaceutical

Moderna's mRNA Flu Vaccine Approval: A Game Changer for Investors

Moderna's FDA approval of the first mRNA flu vaccine could redefine its market potential and growth trajectory.

James McAllister • Aug 16
Trade with the conviction of the 1%.

Institutional-grade market intelligence delivered before the opening bell.

By subscribing, I agree to receive marketing emails and alerts. View our Privacy Policy. You may unsubscribe at any time.

More Stories
Markets & Money

Phillips 66 and Marathon Petroleum in Merger Talks: What a Refining Megadeal Could Mean for Traders

Phillips 66 and Marathon Petroleum held takeover discussions, signaling potential industry consolidation. Traders are wa…

Marcus Rivera • Aug 15, 2026
Energy

Brookfield and La Caisse's Boralex Acquisition: A New Era for Canadian Renewable Energy

Brookfield and La Caisse's acquisition of Boralex signals a significant move in Canada's renewable energy landscape.

Sarah Chen • Aug 15, 2026
Pharmaceutical

Bristol Myers Squibb's FDA Approval: Is the Market Overreacting?

Bristol Myers Squibb's recent FDA approval raises questions about investor sentiment and stock valuation.

James McAllister • Aug 15, 2026
Pharmaceutical

BridgeBio Pharma Stock Gains 29%: Analyzing Wall Street's Confidence

BridgeBio Pharma's stock has surged 29% in three months, reflecting strong earnings and bullish analyst support.

Marcus Rivera • Aug 14, 2026
Pharmaceutical

Lantheus Holdings' Tauklarify Approval: A Game Changer for Alzheimer's Imaging

Lantheus Holdings receives FDA approval for Tauklarify, enhancing its position in the Alzheimer's diagnostics market.

Sarah Chen • Aug 14, 2026
Pharmaceutical

Capricor Therapeutics' Stock Soars 77%: What It Means for Investors

Capricor Therapeutics shares surged 77% after FDA agreed to review DMD drug data, signaling a turnaround for the biotech…

James McAllister • Aug 14, 2026
Markets & Money

Analyzing Treasury Yield Movements Amid Geopolitical Tensions

As Treasury yields rise, geopolitical tensions and manufacturing data shape market landscapes.

Marcus Rivera • Aug 14, 2026
Pharmaceutical

Capricor Therapeutics: A High-Stakes Bet on FDA Decision

Capricor Therapeutics' stock surged 67% after-hours amidst anticipation of an FDA decision on deramiocel.

Sarah Chen • Aug 14, 2026
Critical Minerals

Mobix Labs Ventures into Critical Minerals: Strategic Acquisition Explained

Mobix Labs' strategic acquisition marks a pivotal shift into critical minerals, reshaping its market landscape.

Marcus Rivera • Aug 13, 2026